Abstract:OBJECTIVE: The expression of S100A6 (calcyclin), a member of the S100 calcium binding protein family, is elevated in a number of malignant tumors, but there have been few reports about its expression in gastric cancer. The aim of this study was to investigate its expression regulations in human gastric cancer and noncancerous mucosa, and the response to chemotherapeutic drugs in the gastric cancer cell line.MATERIALS AND METHODS: In one matched gastric cancer sample pair, the serial analysis of gene expression (SAGE) experiment was conducted to compare the gene expression profiles between cancerous and adjacent tissues. To detect the expression regulations among more cancerous tissues, microarrays were carried out and real-time RT-PCR was conducted to validate the results. At the protein level, Western blot and tissue microarray (TMA) examination were further used to verify S100A6 expression. The regulation. detection of S100A6 with flurouracil and doxorubicin at the mRNA and protein level was performed in the SGC7901 cell line.RESULTS: With the SAGE strategy, five times more S100A6 tags were identified in cancer tissues than in normal tissues. With the cDNA microarray, S100A6 was found to be significantly upregulated in 21 of 42 (50%) nonselective gastric cancers. In 10 other paired samples, the upregulation of S 100A6 was consolidated with RT-PCR and Western blot analysis as well. A total of 14 endoscopy-sectioned gastric noncancerous lesions and corresponding normal gastric mucosa were also applied to profile the gene expression; both cDNA microarray and RT-PCR demonstrated no significant alterations of S 100A6 at the mRNA level. TMA examination showed that 34 of 52 (65.4%) cancer samples were positively stained, while only 17 of 80 (21.3%) noncancerous lesions were positively detected and all nine normal mucosae were detected to be negative. An in vitro experiment showed that in the gastric cell line SGC-7901, S100A6 mRNA was detected to be upregulated from 24 to 72 h after treatment with 5 mg/L 5-flurouracil or 0.3 mg/L doxorubicin, and there were two wave upregulations of the S100A6 protein.CONCLUSION: The observed regulated expression of S100A6 suggests that it is associated with gastric cancer tumorigenesis and quantitation of S100A6 is a promising tool for diagnosis of gastric cancer.

S100a6 Overexpression is Associated with Poor Prognosis and is Epigenetically Up-Regulated in Gastric Cancer

Increased Expression of S100a6 Promotes Cell Proliferation in Gastric Cancer Cells

Upregulated Expression Of S100a6 In Human Gastric Cancer

Polypeptide N -acetylgalactosaminyltransferase-6 expression in gastric cancer.

[Regulation Mechanism Study of S100A6 on Invasion and Metastasis in Gastric Cancer].

GSE1 Predicts Poor Survival Outcome in Gastric Cancer Patients by SLC7A5 Enhancement of Tumor Growth and Metastasis.

Presence of S100A9-positive Inflammatory Cells in Cancer Tissues Correlates with an Early Stage Cancer and a Better Prognosis in Patients with Gastric Cancer

Biomarkers , Genomics , Proteomics , and Gene Regulation S 100 A 6 Overexpression Is Associated with Poor Prognosis and Is Epigenetically Up-Regulated in Gastric Cancer

The expression and biological significance of S100A6 protein in gastric carcinoma tissue

Overexpression of S100A4 is Closely Associated with the Progression and Prognosis of Gastric Cancer in Young Patients.

Differential Expression of COL6 Family is a Potential Tumor Marker for Predicting Gastric Cancer

S100A6 is a potential diagnostic and prognostic biomarker for human glioma

[Clinical Significance of S100A8 and S100A9 Expression in Gastric Cancer].

Increased Expression of S100A6 Promotes Cell Proliferation and Migration in Human Hepatocellular Carcinoma

Clinical Significance of S100A2 Expression in Gastric Cancer

Distinct Prognostic Roles of S100 Mrna Expression in Gastric Cancer.

Frequent S100A4 Expression with Unique Splicing Pattern in Gastric Cancers: A Hypomethylation Event Paralleled with E-cadherin Reduction and Wnt Activation.

Annexin A6 is down-regulated through promoter methylation in gastric cancer.

Upregulated Hoxc6 Expression is Associated with Poor Survival in Gastric Cancer Patients.

In Silico Analysis and Verification of S100 Gene Expression in Gastric Cancer

High expression of oncogene cadherin-6 correlates with tumor progression and a poor prognosis in gastric cancer